Wall Street is positive on Editas Medicine Inc (EDIT). On average, analysts give EDIT a Buy rating. The average price target is $15, which means analysts expect the stock to add by 104.36% over the next twelve months. That average ranking earns EDIT an Analyst Rating of 33, which is better than 33% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating EDIT a Buy today. Find out what this means to you and get the rest of the rankings on EDIT!